Your browser doesn't support javascript.
loading
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Bender Ignacio, Rachel A; Chew, Kara W; Moser, Carlee; Currier, Judith S; Eron, Joseph J; Javan, Arzhang Cyrus; Giganti, Mark J; Aga, Evgenia; Gibbs, Michael; Tchouakam Kouekam, Hervé; Johnsson, Eva; Esser, Mark T; Hoover, Keila; Neytman, Gene; Newell, Matthew; Daar, Eric S; Fischer, William; Fletcher, Courtney V; Li, Jonathan Z; Greninger, Alexander L; Coombs, Robert W; Hughes, Michael D; Smith, Davey; Wohl, David Alain.
Afiliação
  • Bender Ignacio RA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.
  • Chew KW; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Moser C; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles).
  • Currier JS; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Eron JJ; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles).
  • Javan AC; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill.
  • Giganti MJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Aga E; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Gibbs M; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Tchouakam Kouekam H; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Johnsson E; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Toronto, Ontario, Canada.
  • Esser MT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Hoover K; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Neytman G; Miami Clinical Research and Baptist Health South Florida, Miami.
  • Newell M; Quantum Clinical Trials, Miami Beach, Florida.
  • Daar ES; Division of Infectious Diseases, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill.
  • Fischer W; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, California.
  • Fletcher CV; Division of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina School of Medicine, Chapel Hill.
  • Li JZ; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha.
  • Greninger AL; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Coombs RW; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle.
  • Hughes MD; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle.
  • Smith D; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
  • Wohl DA; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego.
JAMA Netw Open ; 6(4): e2310039, 2023 04 03.
Article em En | MEDLINE | ID: mdl-37099295
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Idioma: En Ano de publicação: 2023 Tipo de documento: Article